Compare Levi Strauss & Co. (LEVI) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Nuwellis Inc — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Levi Strauss & Co. is far larger — about 3322.7× Nuwellis Inc's market cap, and Levi Strauss & Co. pays a 3.36% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Nuwellis Inc for 26 Days on average.
| LEVI | NUWE | |
|---|---|---|
Market Cap | $7.31B | $2.20M |
Volume | 13,683,095 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $146.65 |
52-Week Low | $17.92 | $0.68 |
Typical Hold Time | 70 Days | 26 Days |
Enterprise Value | $8.86B | -$1.52M |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for four consecutive quarters, including Q3 2026 EPS of $0.48 versus $0.36 expected. Financial health is robust with a net income margin of 8.83% and ROE of 25.76%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 results driven by denim demand trends.
The investment outlook is positive based on fundamentals and analyst sentiment, with a consensus price target of $29.00 implying significant upside. Risks include competitive pressures, recent cybersecurity incidents, and macroeconomic sensitivity. Wall Street maintains a strong buy consensus, supporting a favorable risk-reward profile for long-term investors.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
